45.35

2.67% 1.18

After Hours: 45.36 0.010 +0.02%

Revolution Medicines Inc (RVMD)

Overview News Price History Option Chain Financials Why RVMD Down? Discussions Forecast

Revolution Medicines Inc stock is traded at $45.35, with a volume of 930.83K. It is up +2.67% in the last 24 hours and up +6.38% over the past month. Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Previous Close:

$44.17

Open:

$44.03

24h Volume:

930.83K

Relative Volume:

0.71

Market Cap:

$7.38B

Revenue:

$29.52M

Net Income/Loss:

$-484.27M

P/E Ratio:

-13.91

EPS:

-3.26

Net Cash Flow:

$-457.88M

1W Performance:

+6.38%

1M Performance:

+6.38%

6M Performance:

+40.71%

1Y Performance:

+63.84%

1-Day Range:

$43.91

$45.50

1-Week Range:

$42.95

$46.24

52-Week Range:

$15.44

$48.61

Revolution Medicines Inc Stock (RVMD) Company Profile

Name

Revolution Medicines Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

415-766-3638

Address

700 SAGINAW DR, REDWOOD CITY, CA

Employee

443

Twitter

Next Earnings Date

2024-08-07

Latest SEC Filings

RVMD's Discussions on Twitter

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy
Jan-04-24	Initiated	Wedbush	Outperform
Nov-16-23	Initiated	Raymond James	Outperform
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-14-22	Initiated	Needham	Buy
Oct-21-22	Initiated	Oppenheimer	Outperform
May-20-22	Initiated	BofA Securities	Neutral
Mar-01-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Aug-12-21	Downgrade	Goldman	Buy → Neutral
May-18-21	Initiated	Goldman	Buy
May-21-20	Initiated	H.C. Wainwright	Buy
Mar-09-20	Initiated	Cowen	Outperform
Mar-09-20	Initiated	Guggenheim	Buy
Mar-09-20	Initiated	JP Morgan	Neutral

View All

Revolution Medicines Inc Stock (RVMD) Latest News

01:37 AM

Revolution Medicines' SWOT analysis: biotech stock's cancer focus drives growth - Investing.com

01:37 AM

09:16 AM

Revolution Medicines' SWOT analysis: biotech stock's cancer focus drives growth - Investing.com India

09:16 AM

Sep 29, 2024

Susquehanna Fundamental Investments LLC Has $8.87 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Sep 29, 2024

Sep 28, 2024

Revolution Medicines (NASDAQ:RVMD) PT Raised to $60.00 - MarketBeat

Sep 28, 2024

Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD) - Simply Wall St

Sep 28, 2024

Fred Alger Management LLC Invests $845,000 in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Sep 28, 2024

Sep 27, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Position Decreased by Marshall Wace LLP - MarketBeat

Sep 27, 2024

Sep 25, 2024

Revolution Medicines (NASDAQ:RVMD) Trading Up 3.8% - MarketBeat

Sep 25, 2024

Ensign Peak Advisors Inc Purchases 229,721 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Sep 25, 2024

Sep 24, 2024

Revolution Medicines added to JPMorgan focus list due to NSCLC asset - Seeking Alpha

Sep 24, 2024

1,200,000 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Logos Global Management LP - MarketBeat

Sep 24, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Sep 24, 2024

Integral Health Asset Management LLC Sells 95,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Sep 24, 2024

Sep 23, 2024

Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat

Sep 23, 2024

Sep 22, 2024

XTX Topco Ltd Buys Shares of 23,717 Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Sep 22, 2024

(RVMD) Investment Report - Stock Traders Daily

Sep 22, 2024

Sep 20, 2024